{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:27:55Z","timestamp":1789010875147,"version":"build-2803163510"},"reference-count":61,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The association between malignancy and thrombosis has been recognized for over a century and a half. Patients with cancer have an elevated risk of both initial and recurrent venous thromboembolism (VTE) compared with patients without cancer owing to cancer- and patient-specific factors. Recurrent VTE is common despite anticoagulation, presenting additional management challenges. Patients with cancer also have an increased risk of bleeding when on anticoagulants compared with patients without cancer. This bleeding risk is heightened by the thrombocytopenia common in patients with hematologic malignancies and those treated with intensive myelosuppressive chemotherapy regimens. Despite the advancements in cancer-directed therapy made over the past 15 years, numerous large studies have confirmed that bleeding and VTE recurrence rates remain high in cancer patients. Balancing the increased and competing risks of clotting and bleeding in these patients can be difficult, because management of cancer-associated thrombosis requires anticoagulation despite known increased risks for bleeding. In the context of challenging illustrative cases, this review will describe management approaches to clinical scenarios in which data are sparse: cancer patients with recurrent VTE despite anticoagulation and cancer patients with a new VTE in the setting of severe thrombocytopenia.<\/jats:p>","DOI":"10.1182\/hematology.2019000369","type":"journal-article","created":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T15:18:32Z","timestamp":1575645512000},"page":"71-79","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":19,"title":["Managing the competing risks of thrombosis, bleeding, and anticoagulation in patients with malignancy"],"prefix":"10.1182","volume":"2019","author":[{"given":"Hanny","family":"Al-Samkari","sequence":"first","affiliation":[{"name":"Division of Hematology, Massachusetts General Hospital, Boston, MA;"},{"name":"Harvard Medical School, Boston, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean M.","family":"Connors","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, MA; and"},{"name":"Division of Hematology, Brigham and Women\u2019s Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"2","key":"2019120610122616200_B1","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"Lee","year":"2003","journal-title":"N Engl J Med"},{"issue":"12","key":"2019120610122616200_B2","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.amjmed.2006.02.022","article-title":"Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer","volume":"119","author":"Hull","year":"2006","journal-title":"Am J Med"},{"issue":"3","key":"2019120610122616200_B3","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/rth2.12215","article-title":"Rivaroxaban treatment of cancer-associated venous thromboembolism: Memorial Sloan Kettering Cancer Center institutional experience","volume":"3","author":"Soff","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"issue":"20","key":"2019120610122616200_B4","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019120610122616200_B5","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N Engl J Med"},{"issue":"8","key":"2019120610122616200_B6","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1055\/s-0038-1667001","article-title":"Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE cancer study","volume":"118","author":"Kraaijpoel","year":"2018","journal-title":"Thromb Haemost"},{"issue":"9","key":"2019120610122616200_B7","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1055\/s-0038-1668523","article-title":"Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study","volume":"118","author":"Agnelli","year":"2018","journal-title":"Thromb Haemost"},{"key":"2019120610122616200_B8"},{"issue":"9","key":"2019120610122616200_B9","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1111\/jth.14219","article-title":"Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH","volume":"16","author":"Khorana","year":"2018","journal-title":"J Thromb Haemost"},{"key":"2019120610122616200_B10","doi-asserted-by":"crossref","first-page":"JCO1901461","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update","volume":"2019","author":"Key","year":"2019","journal-title":"J Clin Oncol"},{"key":"2019120610122616200_B11","article-title":"2019 International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer [published online ahead of print 3 September 2019]","author":"Farge","journal-title":"Lancet Oncol"},{"issue":"3","key":"2019120610122616200_B12","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/rth2.12218","article-title":"Asymptomatic \u201cbreakthrough\u201d thrombosis and anticoagulant \u201cfailure\u201d: keep calm and carry on","volume":"3","author":"Olson","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"issue":"7","key":"2019120610122616200_B13","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1634\/theoncologist.2017-0473","article-title":"Use of direct oral anticoagulants in patients with cancer: practical considerations for the management of patients with nausea or vomiting","volume":"23","author":"Riess","year":"2018","journal-title":"Oncologist"},{"issue":"7","key":"2019120610122616200_B14","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1111\/jth.14468","article-title":"Periprocedural interruption of anticoagulation in patients with cancer-associated venous thromboembolism: an analysis of thrombotic and bleeding outcomes","volume":"17","author":"Shaw","year":"2019","journal-title":"J Thromb Haemost"},{"issue":"10","key":"2019120610122616200_B15","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1182\/blood-2002-01-0108","article-title":"Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis","volume":"100","author":"Prandoni","year":"2002","journal-title":"Blood"},{"issue":"3","key":"2019120610122616200_B16","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s11239-019-01857-2","article-title":"Effects of body mass index on the safety and effectiveness of direct oral anticoagulants: a retrospective review","volume":"48","author":"Netley","year":"2019","journal-title":"J Thromb Thrombolysis"},{"issue":"1","key":"2019120610122616200_B17","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1634\/theoncologist.2013-0239","article-title":"New oral anticoagulants and the cancer patient","volume":"19","author":"Short","year":"2014","journal-title":"Oncologist"},{"issue":"9","key":"2019120610122616200_B18","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.3324\/haematol.2017.169060","article-title":"Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study","volume":"102","author":"van Es","year":"2017","journal-title":"Haematologica"},{"issue":"8","key":"2019120610122616200_B19","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"2019120610122616200_B20","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer","volume":"380","author":"Khorana","year":"2019","journal-title":"N Engl J Med"},{"key":"2019120610122616200_B21","article-title":"The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: guidance from the SSC of the ISTH [published online ahead of print 15 July 2019]","author":"Wang","journal-title":"J Thromb Haemost"},{"issue":"6","key":"2019120610122616200_B22","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/jth.12923","article-title":"Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study","volume":"13","author":"Francis","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"25","key":"2019120610122616200_B23","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1056\/NEJM200012213432504","article-title":"Prognosis of cancers associated with venous thromboembolism","volume":"343","author":"S\u00f8rensen","year":"2000","journal-title":"N Engl J Med"},{"issue":"5","key":"2019120610122616200_B24","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1538-7836.2009.03326.x","article-title":"Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients","volume":"7","author":"Carrier","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2019120610122616200_B25","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.thromres.2014.04.028","article-title":"Dose escalation of low molecular weight heparin in patients with recurrent cancer-associated thrombosis","volume":"134","author":"Ihaddadene","year":"2014","journal-title":"Thromb Res"},{"issue":"6","key":"2019120610122616200_B26","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1111\/jth.12955","article-title":"Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis","volume":"13","author":"Schulman","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2019120610122616200_B27","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/j.1365-2125.2011.03965.x","article-title":"Trousseau\u2019s syndrome in a patient with adenocarcinoma of unknown primary and therapy-resistant venous thrombosis treated with dabigatran and fondaparinux","volume":"72","author":"Beyer-Westendorf","year":"2011","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"2019120610122616200_B28","doi-asserted-by":"crossref","first-page":"E156","DOI":"10.1002\/ajh.25101","article-title":"Dual anticoagulation with fondaparinux and dabigatran for treatment of cancer-associated hypercoagulability","volume":"93","author":"Al-Samkari","year":"2018","journal-title":"Am J Hematol"},{"issue":"8","key":"2019120610122616200_B29","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1097\/MBC.0b013e3283401220","article-title":"The management of recurrent VTE in cancer patients receiving therapeutic anticoagulation: the use of dual anticoagulant therapy combined with an IVC filter","volume":"21","author":"Pillai","year":"2010","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"7","key":"2019120610122616200_B30","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.2015.9243","article-title":"Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial","volume":"314","author":"Lee","year":"2015","journal-title":"JAMA"},{"issue":"2","key":"2019120610122616200_B31","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.cllc.2016.10.007","article-title":"ALK-rearranged non-small-cell lung cancer is associated with a high rate of venous thromboembolism","volume":"18","author":"Zer","year":"2017","journal-title":"Clin Lung Cancer"},{"key":"2019120610122616200_B32","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.thromres.2017.12.004","article-title":"Fatal acute disseminated intravascular coagulation as presentation of advanced ALK-positive non-small cell lung cancer: does oncogene addiction matter?","volume":"163","author":"De Giglio","year":"2018","journal-title":"Thromb Res"},{"issue":"6","key":"2019120610122616200_B33","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/CAD.0000000000000356","article-title":"Rapid and dramatic response to alectinib in an anaplastic lymphoma kinase rearranged non-small-cell lung cancer patient who is critically ill","volume":"27","author":"Yoshida","year":"2016","journal-title":"Anticancer Drugs"},{"issue":"4","key":"2019120610122616200_B34","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/rth2.12143","article-title":"Cancer-associated thrombosis: the search for the holy grail continues","volume":"2","author":"\u00dcnl\u00fc","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"issue":"9","key":"2019120610122616200_B35","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1111\/j.1538-7836.2006.02082.x","article-title":"Fatal pulmonary embolism and fatal bleeding in cancer patients with venous thromboembolism: findings from the RIETE registry","volume":"4","author":"Monreal","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2019120610122616200_B36","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.amjmed.2016.10.017","article-title":"The clinical course of venous thromboembolism may differ according to cancer site","volume":"130","author":"Mah\u00e9","year":"2017","journal-title":"Am J Med"},{"issue":"6","key":"2019120610122616200_B37","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/jama.293.6.715","article-title":"Malignancies, prothrombotic mutations, and the risk of venous thrombosis","volume":"293","author":"Blom","year":"2005","journal-title":"JAMA"},{"issue":"4","key":"2019120610122616200_B38","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/j.1365-2141.2010.08524.x","article-title":"The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols","volume":"152","author":"Grace","year":"2011","journal-title":"Br J Haematol"},{"issue":"3","key":"2019120610122616200_B39","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.annemergmed.2004.10.001","article-title":"The mortality of untreated pulmonary embolism in emergency department patients","volume":"45","author":"Calder","year":"2005","journal-title":"Ann Emerg Med"},{"issue":"5","key":"2019120610122616200_B40","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/bjh.13556","article-title":"Guideline on aspects of cancer-related venous thrombosis","volume":"170","author":"Watson","year":"2015","journal-title":"Br J Haematol"},{"issue":"3","key":"2019120610122616200_B41","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","article-title":"Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy","volume":"5","author":"Khorana","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2019120610122616200_B42","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/00005792-199909000-00001","article-title":"Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data","volume":"78","author":"Levitan","year":"1999","journal-title":"Medicine (Baltimore)"},{"issue":"20","key":"2019120610122616200_B43","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1200\/JCO.18.01977","article-title":"Treatment and long-term clinical outcomes of incidental pulmonary embolism in patients with cancer: an international prospective cohort study","volume":"37","author":"Kraaijpoel","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019120610122616200_B44","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/jth.13172","article-title":"Risk of recurrent venous thromboembolism and major hemorrhage in cancer-associated incidental pulmonary embolism among treated and untreated patients: a pooled analysis of 926 patients","volume":"14","author":"van der Hulle","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2019120610122616200_B45","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s11739-012-0784-y","article-title":"A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score","volume":"7","author":"Verso","year":"2012","journal-title":"Intern Emerg Med"},{"issue":"4","key":"2019120610122616200_B46","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s11239-017-1539-4","article-title":"Patients treated for acute VTE during periods of treatment-related thrombocytopenia have high rates of recurrent thrombosis and transfusion-related adverse outcomes","volume":"44","author":"Samuelson Bannow","year":"2017","journal-title":"J Thromb Thrombolysis"},{"issue":"6","key":"2019120610122616200_B47","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/j.1365-2141.2005.05529.x","article-title":"Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective multicentre study","volume":"129","author":"Cortelezzi","year":"2005","journal-title":"Br J Haematol"},{"issue":"5","key":"2019120610122616200_B48","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1160\/TH13-04-0352","article-title":"Platelet count and outcome in patients with acute venous thromboembolism","volume":"110","author":"Di Micco","year":"2013","journal-title":"Thromb Haemost"},{"issue":"4","key":"2019120610122616200_B49","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/trf.13996","article-title":"Preprocedural platelet transfusion for patients with thrombocytopenia undergoing interventional radiology procedures is not associated with reduced bleeding complications","volume":"57","author":"Warner","year":"2017","journal-title":"Transfusion"},{"issue":"2","key":"2019120610122616200_B50","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/jth.13921","article-title":"Clinical prediction rules for mortality in patients with pulmonary embolism and cancer to guide outpatient management: a meta-analysis","volume":"16","author":"Nguyen","year":"2018","journal-title":"J Thromb Haemost"},{"key":"2019120610122616200_B51","article-title":"Management of venous thromboembolism in far-advanced cancer: current practice [published online ahead of print 25 June 2019]","author":"Noble","journal-title":"BMJ Support Palliat Care"},{"issue":"7","key":"2019120610122616200_B52","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1080\/10428190410001663671","article-title":"Enoxaparin can be used safely in patients with severe thrombocytopenia due to intensive chemotherapy regimens","volume":"45","author":"Herishanu","year":"2004","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"2019120610122616200_B53","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1111\/j.1538-7836.2004.00853.x","article-title":"Fixed-dose low-molecular-weight heparin for secondary prevention of venous thromboembolism in patients with disseminated cancer: a prospective cohort study","volume":"2","author":"Monreal","year":"2004","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2019120610122616200_B54","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1007\/s11239-017-1478-0","article-title":"Enoxaparin dose reduction for thrombocytopenia in patients with cancer: a quality assessment study","volume":"43","author":"Mantha","year":"2017","journal-title":"J Thromb Thrombolysis"},{"issue":"9","key":"2019120610122616200_B55","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1111\/jth.12338","article-title":"Management of challenging cases of patients with cancer-associated thrombosis including recurrent thrombosis and bleeding: guidance from the SSC of the ISTH","volume":"11","author":"Carrier","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"17","key":"2019120610122616200_B56","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1200\/JCO.2013.49.1118","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update","volume":"31","author":"Lyman","year":"2013","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019120610122616200_B57","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/jth.14015","article-title":"Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH","volume":"16","author":"Samuelson Bannow","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"7","key":"2019120610122616200_B58","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/ajh.25494","article-title":"Bleeding incidence and risk factors among cancer patients treated with anticoagulation","volume":"94","author":"Angelini","year":"2019","journal-title":"Am J Hematol"},{"issue":"19","key":"2019120610122616200_B59","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1001\/archinternmed.2012.4261","article-title":"Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for gastrointestinal tract bleeding","volume":"172","author":"Witt","year":"2012","journal-title":"Arch Intern Med"},{"key":"2019120610122616200_B60","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ijcard.2018.03.060","article-title":"Impact of BMI on clinical outcomes of NOAC therapy in daily care: results of the prospective Dresden NOAC Registry (NCT01588119)","volume":"262","author":"Tittl","year":"2018","journal-title":"Int J Cardiol"},{"issue":"8","key":"2019120610122616200_B61","doi-asserted-by":"crossref","first-page":"E271","DOI":"10.3390\/cancers10080271","article-title":"The role of direct oral anticoagulants in treatment of cancer-associated thrombosis","volume":"10","author":"Al-Samkari","year":"2018","journal-title":"Cancers (Basel)"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2019\/1\/71\/1546204\/hem2019000369c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2019\/1\/71\/1546204\/hem2019000369c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T18:43:42Z","timestamp":1695494622000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2019\/1\/71\/422620\/Managing-the-competing-risks-of-thrombosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,6]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12,6]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2019000369","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,6]]}}}